Valrubicin
Back to searchMolecule Structure
Scientific Name
Valrubicin
Description of the Drug
Valrubicin is an anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00385
http://www.drugbank.ca/drugs/DB00385
Brand Name(s)
Valstar, Valstar preservative free
Company Owner(s)
Hikma Pharmaceuticals Usa Inc, Endo Pharmaceutical Solutions Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
| DNA topoisomerase II alpha | SINGLE PROTEIN | INHIBITOR | CHEMBL1806 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL12824 | |
| DrugBank | DB00385 | |
| PubChem: Thomson Pharma | 14913323 | 14815397 |
| PubChem | 454216 | |
| LINCS | LSM-45887 | |
| Nikkaji | J86.660A | |
| BindingDB | 50248236 | |
| EPA CompTox Dashboard | DTXSID9046497 | |
| DrugCentral | 2805 | |
| Metabolights | MTBLC135876 | |
| Brenda | 94387 | |
| ChemicalBook | CB9425095 | |
| rxnorm | VALRUBICIN | VALSTAR |
| PubChem: Drugs of the Future | 12012719 | |
| ChEBI | 135876 | |
| ZINC | ZINC000049783788 |
